Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.…
Pulmonx to Participate in the Piper Sandler 38th Annual Healthcare Conference
Pulmonx (NASDAQ: LUNG) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 296 employees.
The shares were at 2.570 USD on 20 November 2026, up 33.9% over 52 weeks. Its 52-week range is 1.130 USD to 3.250 USD: the price is 20.9% below the high and 127.4% above the low.
Its market capitalisation is 111.93M USD.
Pulmonx reports return on equity of -99.8%, an operating margin of -44.4% and revenue up 6.2% year over year.
Its debt exceeds its cash by 3.66M USD, a debt-to-equity ratio of 1.04. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 6 analysts cover the stock, with an average rating of Buy; their mean price target of 4.250 USD is 65.4% above the current price. The next earnings report is expected on 17 February 2027.